Repligen | RGEN - Current Liabilities

Stock Price
117.60
Daily Change
3.54 3.10%
Monthly
2.87%
Yearly
-18.76%
Q2 Forecast
128.32

Repligen reported $135.83M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Agilent USD 2.23B 113M Dec/2025
Align Technology USD 1.92B 46.45M Dec/2025
Bio Techne USD 140.43M 4.12M Dec/2025
BioMarin Pharmaceutical USD 759.03M 39.41M Dec/2025
Bristol-Myers Squibb USD 28.14B 608M Sep/2025
Bruker USD 1.28B 11.1M Dec/2025
Charles River Laboratories USD 1.12B 1.57M Dec/2025
Danaher USD 7.46B 653M Mar/2026
Dentsply International USD 1.34B 62M Dec/2025
General Electric Aerospace USD 40.03B 1.05B Mar/2026
Henry Schein USD 3.23B 79M Dec/2025
Illumina USD 1.59B 377M Dec/2025
IQVIA Holdings USD 8.34B 170M Dec/2025
Mettler Toledo International USD 1.2B 5.99M Dec/2025
Myriad Genetics USD 133.8M 14.2M Dec/2025
OraSure Technologies USD 39.8M 453K Dec/2025
Pacific Biosciences Of California USD 72.83M 9.62M Dec/2025
Pfizer USD 36.6B 1.13B Sep/2025
Repligen USD 135.83M 4.69M Dec/2025
Revvity USD 1.33B 108.5M Dec/2025
Standard Biotools USD 108.31M 343K Dec/2025
Thermo Fisher Scientific USD 14.62B 568M Mar/2026
Waters USD 1.24B 11.8M Dec/2025
West Pharmaceutical Services USD 674M 19.1M Mar/2026